<DOC>
	<DOCNO>NCT02933931</DOCNO>
	<brief_summary>This prospective observational cohort study follow roughly 100 adult receive VSV-ZEBOV vaccine Geneva phase 1 randomize control trial 2014-2015 order determine long-term ( 5-year ) immune response vaccination .</brief_summary>
	<brief_title>Immune Durability After VSV-EBOV Vaccination</brief_title>
	<detailed_description>Background : During Ebola epidemic 2014-5 , proven therapy prevention available beyond horizontal infection control measure . After Canadian government donate 800 vial vaccine candidate VSV-EBOV World Health Organization ( WHO ) , University Hospitals Geneva agree perform WHO-coordinated phase I/II double-blind , placebo-controlled randomize trial ass candidate 's safety immunogenicity healthy adult volunteer . The dos 10 E7 pfu 5 x 10 E7 pfu test 35 16 volunteer , respectively , safety-driven study hold late 2014 . At trial resumption early 2015 , remain volunteer ( n=51 ) receive 3 x 10 E5 pfu . Thirteen volunteer receive placebo . Among vaccinee , early immune response impressive , even low dose 3 x 10 E5 pfu , persist well 6 month ( last time point assess ) . The trial successfully end 12 month injection . This prospective observational study ass immune durability group vaccinees yearly time point five year post-vaccination .</detailed_description>
	<criteria>Participated vaccinated single injection VSVEBOV dose either 3 x 10E5 pfu , 10E7 pfu 5 x 10E7 pfu Geneva phase I VSVEBOV vaccine trial ( NCT02287480 ) . Able provide write , informed consent observational study . Received additional vaccination VSVEBOV similar differing dos . Was lose followup Geneva phase I VSVEBOV vaccine trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>